Objective: Parkinson's disease is characterized by profound motor deficits that result mainly as a consequence of degeneration of midbrain dopaminergic neurons. No current therapy slows or halts disease progression. Neurturin (NTN) and glial cell line-derived neurotrophic factor have potent neuroprotective and neurorestorative effects on dopaminergic neurons, but their use in treating Parkinson's disease has been limited by significant delivery obstacles. In this study, we examined the long-term expression, bioactivity, and safety/tolerability of CERE-120, an adeno-associated virus type 2 vector encoding human NTN, after bilateral stereotactic delivery to the striatum of nonhuman primates.
Methods: Twelve naïve rhesus macaques received bilateral stereotactic injections of 1 of 2 CERE-120 doses or vehicle to the caudate and putamen. Neurological and clinical parameters were monitored for up to 1 year postadministration, after which animals were sacrificed for histological analyses.
Results: Dose-related NTN expression was observed at 1 year and was associated with enhanced tyrosine hydroxylase immunolabeling in the striatum, hypertrophy of tyrosine hydroxylase-positive cells in the substantia nigra, and induction of extracellular signal-regulated kinase signaling in the substantia nigra. Extensive, formal analyses, conducted in accordance with Good Laboratory Practice Regulations, across multiple time points revealed no evidence of clinical, neurological, or systemic toxicity.
Conclusion: The present study provides evidence of long-term expression and bioactivity of NTN on the dopaminergic nigrostriatal system after bilateral stereotactic delivery of CERE-120 to the striatum. Furthermore, no evidence of any adverse effects for up to 1 year postadministration was observed. These findings reveal a wide safety margin for CERE-120 and collectively support the ongoing clinical testing of the efficacy and safety of CERE-120 in patients with Parkinson's disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1227/01.NEU.0000340682.06068.01 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in Parkinson's Disease Diagnosis Through Diffusion Kurtosis Imaging and Radiomics.
Acad Radiol
December 2024
Mallinckrodt Institute of Radiology, Washington University in Saint Louis, St. Louis, MO (A.N.). Electronic address:
The therapeutic effects of induced pluripotent stem cell-derived mesenchymal stem cells on Parkinson's disease.
IUBMB Life
January 2025
Cheerland Watson Precision Medicine Ltd, Shenzhen, China.
Parkinson's disease (PD), characterized by progressive degeneration of dopaminergic neurons in substantia nigra, has no disease-modifying therapy. Mesenchymal stem cell (MSC) therapy has shown great promise as a disease-modifying solution for PD. Induced pluripotent stem cell-derived MSC (iMSC) not only has stronger neural repair function, but also helps solve the problem of MSC heterogeneity.
View Article and Find Full Text PDFDeep Learning-Based Prediction of Freezing of Gait in Parkinson's Disease With the Ensemble Channel Selection Approach.
Brain Behav
January 2025
Department of Biomedical Engineering, Meybod University, Meybod, Iran.
Purpose: A debilitating and poorly understood symptom of Parkinson's disease (PD) is freezing of gait (FoG), which increases the risk of falling. Clinical evaluations of FoG, relying on patients' subjective reports and manual examinations by specialists, are unreliable, and most detection methods are influenced by subject-specific factors.
Method: To address this, we developed a novel algorithm for detecting FoG events based on movement signals.
Genetic Insights Into the Role of Cathepsins in Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis: Evidence From Mendelian Randomization Study.
Brain Behav
January 2025
Department of Neurology, Sichuan Taikang Hospital, Chengdu, Sichuan, China.
Background: Previous studies have confirmed the significant role of cathepsins in the development of neurodegenerative diseases. We aimed to determine whether genetically predicted 10 cathepsins may have a causal effect on Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).
Methods: We conducted a two-sample bidirectional Mendelian randomization (MR) study using publicly available data from genome-wide association study (GWAS) to assess the causal associations between 10 cathepsins and three neurodegenerative diseases, including AD, PD, and ALS.
Exploring the intersection between orthostatic hypotension and daytime sleepiness in Parkinson's disease.
J Neurol Sci
December 2024
James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH, USA.
Introduction: Daytime sleepiness, reported in about 50 % of patients with Parkinson's disease (PD), is associated with high morbidity, poor quality of life and increased risk for accidents. While an association between dysautonomia and daytime sleepiness in early, de-novo PD has been reported, our understanding of the role of medications, cognitive status and co-morbidites on this relationship is inadequate.
Methods: Data were analyzed from the prospective Cincinnati Cohort Biomarkers Program.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!